

Austin M. Day

ASSOCIATE

Corporate
Salt Lake City

austin.day@wsgr.com
801-907-6470

FOCUS AREAS

Capital Markets
Corporate
Corporate Governance
Public Company
Representation

EXPERIENCE

Austin Day is an associate in the Salt Lake City office of Wilson Sonsini Goodrich & Rosati, where he practices corporate and securities law with a focus on public company representation, corporate governance, SEC compliance, 1934 Act disclosure matters, public offerings, and private placements.

Prior to joining the firm, Austin practiced law at Dechert LLP in Charlotte and Cooley LLP in San Diego.

CREDENTIALS

Education

- J.D., J. Reuben Clark Law School, Brigham Young University, 2016
Magna Cum Laude; Order of the Coif; Senior Editor, BYU Law Review
- B.A., Chinese (Mandarin), University of Utah, 2013
Summa Cum Laude

Honors

- Pro Bono Publico Award, Casa Cornelia Law Center, 2020

Admissions

- State Bar of California
- State Bar of North Carolina
- State Bar of Utah

MATTERS

Select Matters

- OnKure Therapeutics in its private placement (2026)
- Sana Biotechnology in its at-the-market offering (2026)
- Check Point Software Technologies in its convertible senior notes offering (2025)
- MSC Income Fund in its public offering and listing on the NYSE (2025)*
- Aquestive Therapeutics in its follow-on public offering (2024) and at-the-market offering (2022-2025)*
- Main Street Capital Corporation in its public offerings of notes (2024)*
- AB Private Lending Fund in its initial/continuous public offering (2024-2025)*
- PaxMedica in its follow-on public offering (2024)*
- vTv Therapeutics in its private placement (2024)*
- Raymond James & Associates and B. Riley Securities in their at-the-market offering of Fidus Investment Corporation (2022-2025)*
- Janux Therapeutics in its initial public offering (2021)*
- Regulus Therapeutics in its private placements (2019, 2020, and 2021)*
- Kura Oncology in its follow-on public offerings (2019 and 2020)*

- Synthorx in its initial public offering (2018)*
- Allogene Therapeutics in its initial public offering (2018)*
- Tocagen in its follow-on public offering (2018)*

**Denotes matters handled at another firm prior to joining Wilson Sonsini in 2025.*